Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4
about
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansineAntibody-drug conjugates as novel anti-cancer chemotherapeuticsOncogenomics and the development of new cancer therapiesMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionThe role of trastuzumab in early stage breast cancer: current data and treatment recommendations.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.JNets: exploring networks by integrating annotation.Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report.Production of recombinant antibodies using bacteriophages.Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.Emerging therapies in gastrointestinal cancers.Testing for HER2 in Breast Cancer: A Continuing Evolution.Drugs, their targets and the nature and number of drug targets.Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.Resistance to HER2-targeted therapies: a potential role for FOXM1.Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables.The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition.ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.Managing high-risk breast cancerGenetics of CD33 in Alzheimer's disease and acute myeloid leukemia.Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.Sensitization of chemotherapy by anti-HER.Comparison of the impact of pro- and antiinflammatory immune processes at the two immune-deviated sites, eye and solid tumor and possible consequences for the antitumoral therapy with fever inducers.Mechanisms of trastuzumab resistance and their clinical implications.Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development.Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy.Novel antibodies as anticancer agents.HER2-positive breast cancer: current and future treatment strategies.Molecularly targeted therapeutics for breast cancer.Trastuzumab-induced hepatotoxicity: a case report.Multimodality imaging of the HER-kinase axis in cancer.Monoclonal antibody mechanisms of action in cancer.Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer.Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.HER2 breast cancer therapies: a reviewmiR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancerCost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.
P2860
Q26747729-9D29A065-D32F-4FC0-A1AC-75F5D6C8C118Q26800175-27BA0A34-421E-44A0-BBA2-547F981F6114Q28263634-C79C2719-7D09-4448-9347-75638E4A3BABQ28829301-8C6A8149-4CD8-4A09-8157-29FB185BEF4CQ31120100-F4A2C3F4-119A-435B-BE6E-506A267AE653Q33409083-BE5C4358-77F3-4956-8E8C-A5DE93B08CB3Q33422600-737EB95A-33C3-4510-9E81-939D35EE0E33Q33580422-4221DE56-D87A-4559-B016-57A44855E0A9Q33643027-5B6EFE8C-0F46-46E3-8181-9170F41BDE25Q33767100-95BC9108-C6E9-4679-B147-B07A817EE1F2Q33866870-F83E0B33-C16C-498E-A5B8-854CB0597813Q34424285-AD1B6031-ECFC-48DB-B6AA-AE2B7FDA909AQ34571023-E8375B0F-B858-43D0-B58B-4B16395D0171Q34908845-88797101-B5DF-43C0-B94B-72F5B9D0D98DQ34955355-B2974FF8-83B8-4795-B873-7059AB14CC30Q35245409-69D35758-590E-432F-9CE3-07992DBA1F45Q35571641-58902CD4-2234-4932-AB0E-ECC8A5EE1410Q35755192-43E90737-97ED-4E54-A344-BED099D4D435Q35819307-A2464804-53D2-4752-913B-929536470311Q35837399-EB8D9C73-38A8-49C9-81F9-E4705279852EQ35948050-C929D64D-75D2-4616-BC8A-6CECD077BE0FQ35954213-FF420C82-FEB1-4EB3-9BCE-16640480B7B9Q36072744-30D8A811-7337-42BF-A07F-8373AF226A65Q36355193-73ACFAB2-30D9-4BB3-801E-011FB7E08440Q36441450-D0468A54-0B4B-42CD-ADD2-9E146ADA8020Q36513881-59C24D0D-82A5-4E09-843A-8E47920007C7Q36532005-B3BC67E0-8868-4CE7-8D0C-3983654EB844Q36689038-4C3005DB-7750-408D-A024-982AD1314D1CQ36779299-9D8725D0-A229-41EE-87FF-3D688CD68518Q36832141-8549EB99-DC8A-4087-8AD2-8249A8DF3E0DQ36839672-3DC19627-7D7D-4B6B-976D-101F69209E5BQ36879839-9BD5EFCF-8791-45FB-B05F-25D4E1154086Q36933004-84F6C165-9164-4773-BD42-B1F30E3B97DAQ36936796-AF79C43C-E37B-46EA-97AE-95961EEB7B7BQ36961106-575C30C3-E673-4A45-AEF5-46C0F6680D50Q37025901-BE523BBF-1AC2-45F8-A6F4-BD8D714E17A6Q37194856-07193C8D-5BA1-49A3-8DFB-0C0DE0BA2AA9Q37303196-E75AD856-AD89-45DE-9105-2C6CF95F50E8Q37375623-E6E4D831-756E-4128-8E4A-C3E7B6525B2EQ37385536-D99C23DD-5B76-4DB9-8D9E-EC0FB2ADEA10
P2860
Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@ast
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@en
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@nl
type
label
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@ast
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@en
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@nl
prefLabel
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@ast
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@en
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@nl
P2093
P3181
P1476
Mechanism of action of anti-HE ...... update on trastuzumab and 2C4
@en
P2093
Ana Rovira
Begoña Mellado
Joan Albanell
Jordi Codony
Pere Gascón
P304
P3181
P356
10.1007/978-1-4615-0081-0_21
P407
P577
2003-01-01T00:00:00Z